Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

By Allan G.   Davis J.   Dickins M.   Gardner I.   Jenkins T.   Jones H.   Webster R.   Westgate H.  

Xenobiotica, Vol. 38, Iss. 6, 2008-06 ,pp. : 620-640

Informa Healthcare

Access to resources Recommend Favorite

Application of population pharmacokinetics for preclinical safety and efficacy studies

By Porzio Stefano  

Bioanalysis, Vol. 5, Iss. 16, 2013-08 ,pp. : 2053-2069

Future Science

Access to resources Recommend Favorite

Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism

By Bhamidipati R   Mujeeb S   Dravid P. V   Khan A. A   Singh S. K   Rao Y. K   Mullangi R   Srinivas N. R  

Xenobiotica, Vol. 35, Iss. 3, 2005-03 ,pp. : 253-271

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats

By Oh S. J.   Lee K.   Ryu J.   Yu H. E.   Han G.   Park S. K.   Kang J. S.   Kim H. M.   Kim Y. C.  

Xenobiotica, Vol. 41, Iss. 2, 2011-02 ,pp. : 155-163

Informa Healthcare

Access to resources Recommend Favorite

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

By Ward K. W.   Proksch J. W.   Azzarano L. M.   Mumaw J. A.   Roethke T. J.   Stelman G. J.   Walsh M. J.   Zeigler K. S.   McSurdy-Freed J. E.   Kehler J. R   Chokshi J.   Levy M. A.   Smith B. R.  

Xenobiotica, Vol. 31, Iss. 11, 2001-11 ,pp. : 783-797

Informa Healthcare

Access to resources Recommend Favorite